Billing for Skin Substitutes

Executive Key Takeaways

What is Local Coverage Determination (LCD): Implement proactive protocols to optimize claim acceptance and minimize denials.
Reasons for CMS concerns: Implement proactive protocols to optimize claim acceptance and minimize denials.
Absence of proper research: Implement proactive protocols to optimize claim acceptance and minimize denials.
Non-compliance with ASP: Implement proactive protocols to optimize claim acceptance and minimize denials.

Table of Contents

1. What is Local Coverage Determination (LCD)
2. Reasons for CMS concerns
3. Absence of proper research
4. Non-compliance with ASP
5. Fraud Detection in Medical Billing
6. Patients Safety
7. Sharanya Rajmohan
8. Partner with Shoreline

On April 11, the Centers for Medicare & Medicaid Services (CMS) announced that it is reviewing its coverage policies for skin substitute products. As a result of this ongoing review, the effective date for the final local coverage determination (LCD) regarding Skin Substitute Grafts and Cellular and Tissue-Based Products (CTP) for the treatment of diabetic foot ulcers and venous leg ulcers has been postponed to January 1, 2026.

Compliance Directive 01

What is Local Coverage Determination (LCD)

Local Coverage Determination (LCD) refers to the policy that governs the coverage and payment for a certain medical service or operation within a specified geographic region. LCDs are designed to help healthcare practitioners, suppliers, and beneficiaries determine if a specific service or item is medically essential and eligible for reimbursement.

Compliance Directive 02

Reasons for CMS concerns

Absence of proper research

Non-Compliance with ASP

Misuse and Overuse

Patient Safety

Fraud detection in medical billing.

Compliance Directive 03

Absence of proper research

Skin substitute products refer to medical devices or materials used to replace or augment damaged skin. These products play a critical role in wound care, particularly for patients with burns, ulcers, or other skin injuries. These skin substitutes include bioengineered products, synthetic grafts, and human-derived tissues. Aside from papers published by skin grafting manufacturers, treatments employing skin substitute products are not sufficiently researched or comprehended. Furthermore, there is limited evidence that demonstrates its ability to cure chronic wounds.

Compliance Directive 04

Non-compliance with ASP

The use and price of skin grafting materials have increased in recent years, resulting in significant costs to Medicare programs. OIG had discovered that manufacturers are not complying with the new Average Sales Price(ASP) for skin substitute products, and as a result, it demands significant reimbursement in Part B payments. CMS was unable to determine ASP-based payment amounts for 30 out of the 68 skin substitutes billing codes due to missing ASP data from manufacturers. Because these are not prescribed drugs, the CMS cannot regulate the pricing for these treatments unless the manufacturers submit the required ASP data. We at Shoreline Medical Billing company have effective denial management techniques and pay close attention that all medical billing compliances are met as per the regulatory standards.

Compliance Directive 05

Fraud Detection in Medical Billing

The coding for skin substitutes is intricate, often requiring specialized knowledge. This complexity can present opportunities for unscrupulous billing practices.

Billed units not coinciding with the verified size of the wound.

Inappropriate use of the product

Inability to establish the amount of grafting product needed or utilized.

Documentation that does not support the linked skin replacement.

Cloning documentation among patients.

Lack of fully signed consent paperwork from the patient are the other areas of concern.

Compliance Directive 06

Patients Safety

The use of skin substitutes in medical treatments offers incredible benefits but comes with inherent risks. One reason the market for skin substitutes has grown is that many of these products are made from human tissue. They are "minimally manipulated" and intended for "homologous use," which means they do not need to go through the FDA's premarket approval process or clinical trials. Prioritizing safety is one of the major concern for CMS. Fraud detection in medical billing, particularly concerning skin substitutes, is a multifaceted issue that demands vigilance and collaboration. We at Shoreline Medical Billing company conduct regular medical record audits to ensure that the provider's documentation aligns with billing regulations. With advanced technologies at our disposal and a commitment to ethical practices, we ensure compliance with all requirements. Let’s stay informed, question discrepancies, and work towards a transparent healthcare system for all!

Compliance Directive 07

Sharanya Rajmohan

Sharanya brings clarity to the complexities of medical billing and healthcare regulations. With a knack for turning industry shifts into straightforward, actionable insights, her blogs help readers stay informed without the jargon.

Compliance Directive 08